Newsfile Corp
02 Jun 2026, 16:49 UTC · 2h ago
IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
Search tags
Newsfile Corp
02 Jun 2026, 16:49 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
The Independent Data Monitoring Committee recommended the discontinuation of Immutep's TACTI-004 Phase III clinical trial for futility. — The failure of a Phase III trial for a primary candidate typically destroys a biotech's core valuation and pipeline prospects.
-1.00A federal securities class action lawsuit has been filed against Immutep alleging the company made false or misleading statements regarding the safety and efficacy of the TACTI-004 trial. — Legal liabilities and potential settlements create additional financial drain and governance risk beyond the clinical failure.
-0.40Immutep's ADR price collapsed by 82.6% to $0.48 on March 13, 2026, following the trial discontinuation news. — This confirms the market has already priced in the majority of the clinical failure, limiting further downside from the trial news alone.
-0.20Ticker attribution
Continue reading
6 related stories
Model heads
The company is facing a federal securities class action lawsuit following the discontinuation of a Phase III clinical trial for futility and an 82.6% drop in ADR price.
The company is mentioned in the context of an approaching deadline for a securities class action lawsuit.
The company is mentioned in the context of an approaching deadline for a securities class action lawsuit.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Seeking Alpha
1h ago
